Grace Therapeutics, Inc.
GRCEGrace Therapeutics, Inc. in brief
Grace Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Princeton, New Jersey, USA. Its market value was $39 M on 28 October 2026, which makes it the 22,113th largest listed company in the world and the 3,959th largest in the USA on this site. Its shares trade under the symbol GRCE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Grace Therapeutics, Inc.
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.
From the company's annual report filed with the US SEC: read the report
Grace Therapeutics, Inc. timeline
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- ✎Renamed Grace Therapeutics, Inc.Formerly Acasti Pharma Inc..
Events of Grace Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,909 (Oct 2026) · #3,963 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -25.7%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -12.2%
- Liabilities / assets
- 4.1%
- Revenue growth
- +49900.0%
- R&D / revenue
- 5.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | — | — | $-11M | $-8M | — |
| Mar 2025 | — | — | $-17M | $-10M | — |
| Mar 2024 | — | — | $-13M | $-13M | — |
| Mar 2023 | — | — | $-52M | $-42M | — |
| Mar 2022 | $100M | +49900.0% | $-16M | $-10M | -9.8% |
| Mar 2021 | $0M | — | $-16M | $-20M | -9840.0% |
| Mar 2020 | — | — | $-24M | $-26M | — |
| Mar 2019 | — | — | $-34M | $-39M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $-9M | — | — | $-0.47 | — |
| Mar 2025 | $-15M | — | — | $-0.79 | — |
| Mar 2024 | $-12M | — | — | $-1.35 | — |
| Mar 2023 | $-16M | — | — | $-5.71 | — |
| Mar 2022 | $-17M | — | — | $-0.27 | — |
| Mar 2021 | $-14M | — | — | $-1.33 | — |
| Mar 2020 | $-23M | — | — | $-0.30 | — |
| Mar 2019 | — | — | — | $-0.73 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Sep 18, 20268-KCurrent reportShareholder vote
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Jul 28, 2026DEF 14AProxy statement
- Jul 28, 20268-KCurrent reportOther events
- Jun 18, 20268-KCurrent reportOther events
- Jun 18, 20268-KCurrent reportResults of operations
- Jun 18, 202610-KAnnual report · period to Mar 2026
- Jun 5, 20268-KCurrent reportDirectors or officers changed
Official filings of Grace Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-11 M
- Net income
- $-8 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $67 M
- Total liabilities
- $3 M
- Total equity
- $64 M
As of March-2026
Top 38 institutional investors in Grace Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 2,798,167 | New | 13.30% | $6 M | Nov 16, 2026 |
| 2 | Cerity Partners LLC | 849,055 | 0 (0.00%) | 4.04% | $2 M | Nov 13, 2026 |
| 3 | Eversept Partners, LP | 769,772 | -3,128 (-0.40%) | 3.66% | $2 M | Nov 16, 2026 |
| 4 | Bank Of America Corp /de/ | 494,698 | 0 (0.00%) | 2.35% | $1 M | Nov 16, 2026 |
| 5 | Nantahala Capital Management, LLC | 476,190 | New | 2.26% | $1 M | Nov 13, 2026 |
| 6 | Rosalind Advisors, Inc. | 476,190 | New | 2.26% | $1 M | Nov 16, 2026 |
| 7 | ADAR1 Capital Management, LLC | 476,190 | New | 2.26% | $1 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 400,350 | -11,364 (-2.76%) | 1.90% | $1 M | Nov 13, 2026 |
| 9 | Renaissance Technologies LLC | 186,134 | New | 0.88% | $0 M | Nov 12, 2026 |
| 10 | Two Sigma Investments, LP | 126,791 | +29,901 (+30.86%) | 0.60% | $0 M | Nov 16, 2026 |
| 11 | Cantor Fitzgerald, L. P. | 100,000 | -100,000 (-50.00%) | 0.48% | $0 M | Nov 16, 2026 |
| 12 | Citadel Advisors LLC | 66,696 | -283,044 (-80.93%) | 0.32% | $0 M | Nov 16, 2026 |
| 13 | Jane Street Group, LLC | 62,725 | -26,717 (-29.87%) | 0.30% | $0 M | Nov 12, 2026 |
| 14 | Susquehanna International Group, LLP | 55,319 | +5,742 (+11.58%) | 0.26% | $0 M | Nov 16, 2026 |
| 15 | BlackRock, Inc. | 35,915 | -1,620 (-4.32%) | 0.17% | $0 M | Nov 13, 2026 |
| 16 | XTX Topco Ltd | 35,772 | -35,896 (-50.09%) | 0.17% | $0 M | Nov 16, 2026 |
| 17 | Citigroup Inc | 35,481 | New | 0.17% | $0 M | Nov 4, 2026 |
| 18 | Rangeley Capital, LLC | 25,208 | -792 (-3.05%) | 0.12% | $0 M | Nov 16, 2026 |
| 19 | Kestra Private Wealth Services, LLC | 23,000 | 0 (0.00%) | 0.11% | $0 M | Nov 6, 2026 |
| 20 | Morgan Stanley | 22,763 | +13,315 (+140.93%) | 0.11% | $0 M | Nov 13, 2026 |
| 21 | Johnson Dunn Capital Advisors Inc | 19,500 | — | 0.09% | $0 M | Nov 12, 2026 |
| 22 | BNP Paribas Financial Markets | 15,900 | +5,400 (+51.43%) | 0.08% | $0 M | Nov 12, 2026 |
| 23 | Axq Capital, LP | 12,221 | New | 0.06% | $0 M | Nov 12, 2026 |
| 24 | Oppenheimer & Co Inc | 10,000 | 0 (0.00%) | 0.05% | $0 M | Oct 26, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 8,750 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
Show all 38: investors 26 to 38
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | National Bank Of Canada /fi/ | 2,680 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 27 | UBS Group AG | 2,289 | -14,488 (-86.36%) | 0.01% | $0 M | Nov 10, 2026 |
| 28 | Tower Research Capital LLC (TRC) | 2,258 | +606 (+36.68%) | 0.01% | $0 M | Nov 16, 2026 |
| 29 | Royal Bank Of Canada | 898 | +355 (+65.38%) | 0.00% | $0 M | Nov 16, 2026 |
| 30 | Nuveen, LLC | 863 | New | 0.00% | $0 M | Nov 10, 2026 |
| 31 | Arax Advisory Partners | 250 | -750 (-75.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 32 | Activest Wealth Management | 104 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 33 | SBI Securities Co., Ltd. | 77 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 34 | Jpmorgan Chase & Co | 58 | New | 0.00% | $0 M | Nov 12, 2026 |
| 35 | Harbour Investments, Inc. | 37 | New | 0.00% | $0 M | Nov 9, 2026 |
| 36 | Osaic Holdings, Inc. | 31 | New | 0.00% | $0 M | Nov 12, 2026 |
| 37 | Lanark Financial, Inc. | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 38 | Caitong International Asset Management Co., Ltd | 1 | New | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Grace Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 400,350 | $1 M | 1.9% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 35,188 | $0 M | 0.17% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 16,239 | $0 M | 0.08% | <0.01% | +2.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 11,364 | $0 M | 0.05% | <0.01% | +770% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,571 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,347 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 778 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Grace Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Opaleye Management Inc.10% owner | Buyindirect | +2,974 | $1.725 | $5 K | 3.10 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +29,207 | $1.722 | $50 K | 3.10 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +15,879 | $1.764 | $28 K | 3.07 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +3,087 | $1.775 | $5 K | 3.05 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +5,027 | $1.802 | $9 K | 3.05 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +10,328 | $1.789 | $18 K | 3.05 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +66,411 | $1.768 | $117 K | 3.04 M | Form 4 |
| filed | Opaleye Management Inc.10% owner | Buyindirect | +21,390 | $1.926 | $41 K | 2.97 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Grace Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-04-23 17:52 UTC, code LUDP, resumed 17:57 UTC
- 2026-04-23 17:46 UTC, code LUDP, resumed 17:51 UTC
- 2026-04-23 16:27 UTC, code T3, resumed 17:40 UTC
Fails to deliver
- : 772 shares at $1.87
- : 1,453 shares at $1.93
- : 5,517 shares at $1.97
- : 5,162 shares at $1.99
- : 1,291 shares at $2.02
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Grace Therapeutics, Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-25.7%Free cash flow is -25.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.47 vs -0.79Diluted EPS -0.47 in fiscal 2025 against -0.79 the year before (report's currency).
- ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$20 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-11.9%-11.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities8.1×Current ratio 8.08 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year36.6%Diluted shares up 36.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Grace Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 · USD | FY 2024to Mar 31, 2025 · USD | FY 2023to Mar 31, 2024 · USD | FY 2022to Mar 31, 2023 · USD | FY 2021to Mar 31, 2022 · USD | FY 2020to Mar 31, 2021 · USD | FY 2019to Mar 31, 2020 · USD | FY 2018to Mar 31, 2019 · USD | FY 2017to Mar 31, 2018 · CAD | FY 2016to Feb 28, 2017 · CAD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | 100r0+50920%100% | 0.2—100% | — | — | — | — | |
| Cost of revenue | — | — | — | — | 0−100%0.0% | 0.1—38.8% | — | — | — | — | |
| Research and development | 2.4−74.7%— | 9.5+103%— | 4.7−53.0%— | 10.0+79.4%— | 5.6+33.2%5.6% | 4.2−73.9%2129% | 16−45.6%— | 29—— | 16+117%— | 7.2—— | |
| Selling and marketing | — | — | 0.3−61.9%— | 0.7+27.6%— | 0.5−54.6%0.5% | 1.1−57.1%583% | 2.7+439%— | 0.5—— | — | — | |
| General and administrative | 8.7+21.0%— | 7.2+7.2%— | 6.7r6.4−12.2%— | 7.6−17.8%— | 9.3+67.8%9.3% | 5.5−4.8%2817% | 5.8+27.8%— | 4.5—— | — | — | |
| Operating income | −11—— | −17—— | −13—— | −52—— | −16—−15.6% | −16—−8377% | −24—— | −34—— | −20—— | −10—— | |
| Interest and finance income | 0.7−3.7%— | 0.7−22.0%— | 0.9+270%— | 0.2+219%— | 0.1−28.0%0.1% | 0.1−68.2%54.6% | 0.3−6.1%— | 0.4—— | 0.1−39.5%— | 0.1—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 1.8r1.5+1472%— | 0.1r0.2—— | |
| Other non-operating income (expense) | 1.6−59.5%— | 3.9—— | −1.8−1096%— | 0.2−96.4%— | 5.1—5.1% | −3.3—−1663% | −1.1—— | −5.0—— | — | — | |
| Income before tax | −9.5—— | −13—— | −15—— | −52—— | −10—−10.5% | −20—−10040% | −26—— | −39—— | — | — | |
| Income tax | −1.7—— | −3.2—— | −1.8—— | −9.5—— | −0.6—−0.6% | 0—0.0% | 0—— | 0—— | — | −0.1—— | |
| Net income including minority interests | — | — | — | — | — | — | — | — | −22—— | −10—— | |
| Net income attributable to shareholders | −7.8—— | −9.6—— | −13—— | −42—— | −9.8—−9.8% | −20—−10040% | −26—— | −39—— | — | — | |
| Earnings per share, basic | -0.47—— | -0.79—— | -1.35—— | -5.71r-0.95—— | -0.27—— | -1.33r-0.17—— | -0.30—— | -0.73—— | — | — | |
| Earnings per share, diluted | -0.47—— | -0.79—— | -1.35—— | -5.71r-0.95—— | -0.27—— | -1.33r-0.17—— | -0.30—— | -0.73—— | — | — | |
| Shares, weighted average (basic) | 17+36.6%— | 12+26.8%— | 9.5+28.2%— | 7.4r45−79.8%— | 37—— | — | — | 54—— | 17+62.1%— | 11—— | |
| Shares, weighted average (diluted) | 17+36.6%— | 12+26.8%— | 9.5+28.2%— | 7.4r45−79.8%— | 37+148%— | 15r119−82.5%— | 85+55.8%— | 54—— | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 17−23.3%25.5% | 22−3.8%30.7% | 23−17.5%31.4% | 28−8.1%35.2% | 30−40.4%23.6% | 51+258%81.6% | 14−15.6%62.3% | 17—45.7% | 8.2−22.2%35.8% | 11—40.1% | |
| Short-term investments | — | — | 0−100%0.0% | 0.0−99.9%0.0% | 13+36.1%10.4% | 9.8—15.7% | — | 8.9—24.1% | — | — | |
| Receivables | — | — | 0.7−10.0%1.0% | 0.8+46.4%1.0% | 0.5+3.4%0.4% | 0.5−2.9%0.8% | 0.5−54.1%2.4% | 1.2—3.2% | 0.8+357%3.3% | 0.2—0.6% | |
| Other current assets | — | — | — | — | — | — | 0.2+298%0.9% | 0.0—0.1% | 0.1—0.5% | — | |
| Current assets | 17−23.5%26.1% | 23−5.4%31.5% | 24−18.0%32.8% | 29−35.3%37.0% | 45r46−27.4%35.2% | 62+238%99.9% | 18r16−34.0%80.8% | 28—75.8% | 9.5−13.8%41.3% | 11—41.8% | |
| Property, plant and equipment | 0.0−46.7%0.0% | 0.0−37.5%0.0% | 0.0−76.9%0.0% | 0.1r12−99.5%0.1% | 21—16.2% | — | 1.9−9.3%8.4% | 2.1—5.7% | 2.8+1.6%12.3% | 2.8—10.5% | |
| Right-of-use (leased) assets | — | — | 0−100%0.0% | 0.5+47.0%0.6% | 0.3+266%0.2% | 0.1−41.5%0.1% | 0.1—0.6% | — | — | — | |
| Goodwill | 8.10.0%12.2% | 8.10.0%11.3% | 8.10.0%11.1% | 8.1−37.2%10.3% | 13—10.1% | — | — | — | — | — | |
| Other intangible assets | 410.0%61.7% | 410.0%57.1% | 410.0%56.1% | 41−41.1%52.0% | 70—54.3% | 0−100%0.0% | 4.2−33.5%18.6% | 6.4—17.3% | — | — | |
| Long-term investments | — | — | — | — | — | — | — | 0.0—0.1% | — | — | |
| Total assets | 67−7.4%100% | 72−1.8%100% | 73−7.4%100% | 79−38.5%100% | 129+106%100% | 62+173%100% | 23−38.1%100% | 37—100% | 23−12.9%100% | 26—100% | |
| Accounts payable | 0.7+16.8%1.1% | 0.6−40.3%0.8% | 1.0−18.9%1.4% | 1.2−26.0%1.6% | 1.7r1.7+1359%1.3% | 0.1r0.1−93.3%0.2% | 1.7r1.7−43.8%7.5% | 3.0—8.3% | 6.7+178%29.2% | 2.4—9.1% | |
| Current liabilities | 2.1+11.2%3.2% | 1.9+14.6%2.7% | 1.7−50.6%2.3% | 3.4+4.6%4.3% | 3.3+106%2.5% | 1.6−78.6%2.5% | 7.4−45.9%32.4% | 14—37.0% | 6.7+178%29.2% | 2.4—9.1% | |
| Lease liabilities (non-current) | — | — | 0−100%0.0% | 0.4+115%0.5% | 0.2—0.1% | — | 0.1—0.3% | — | — | — | |
| Total liabilities | 2.8−48.8%4.1% | 5.4−53.4%7.5% | 12+3.5%15.8% | 11−45.1%14.1% | 20+199%15.8% | 6.8−31.0%10.9% | 9.9−61.9%43.1% | 26—70.1% | 15+270%64.2% | 4.0—15.1% | |
| Retained earnings | −228—−343% | −221—−307% | −211—−288% | −198—−251% | −156—−121% | −146—−234% | −126—−553% | −101—−273% | −72—−315% | −50—−190% | |
| Shareholders' equity | 64−4.1%95.9% | 67+7.9%92.5% | 62−9.1%84.2% | 68−37.2%85.9% | 108+94.5%84.2% | 56+328%89.1% | 13+17.6%56.9% | 11—29.9% | — | — | |
| Total equity | — | — | — | — | — | — | — | — | 8.2−63.3%35.8% | 22—84.9% | |
| Total liabilities and equity | 67−7.4%100% | 72−1.8%100% | 73−7.4%100% | 79−38.5%100% | 129+106%100% | 62+173%100% | 23−38.1%100% | 37—100% | 23−12.9%100% | 26—100% | |
| Shares outstanding | 16+16.8%— | 14+45.9%— | 9.4+26.4%— | 7.4r45−83.2%— | 44—— | — | — | — | — | — | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 0.8+9.3%— | 0.7−20.0%— | 0.9−49.6%— | 1.8+35.5%— | 1.3+13.9%1.3% | 1.2−39.9%599% | 2.0—— | — | 0.9+58.0%— | 0.6—— | |
| Cash from operating activities | −8.9—— | −15—— | −12—— | −16—— | −17—−17.2% | −14—−7306% | −23—— | — | −13—— | −6.2—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | −0.5—— | −2.5—— | |
| Cash from investing activities | 0—— | 0−100%— | 0.1−99.2%— | 13—— | −3.5—−3.5% | −9.9−221%−5030% | 8.1—— | — | −0.4−106%— | 6.9—— | |
| Shares issued | — | — | 0−100%— | 0.3—— | 0−100%0.0% | 59+750%30271% | 7.0—— | — | 11+119%— | 5.0—— | |
| Cash from financing activities | 3.7−73.5%— | 14+90.7%— | 7.4+2321%— | 0.3—— | 0−100%0.0% | 59+351%30352% | 13—— | — | 11+65.1%— | 6.9—— | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | −0.0—— | −0.1—— | |
| Change in cash | −5.2—— | −0.9—— | −4.9—— | −2.5—— | −21−156%−20.6% | 37—18726% | −2.6—— | — | −1.5−121%— | 7.5—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 2.5−54.0%— | 0.9+55.8%— | 0.7−27.0%— | 0.4*−74.3%— | 0.5−78.9%— | 0.6−80.9%— | 1.0−64.7%— | 1.6*−3.0%— | 2.2+52.0%— | 3.0—— | 2.7—— | 1.7*—— | 1.4—— | |
| Selling and marketing | — | — | — | — | — | — | — | — | — | — | — | 0.1*—— | 0.0—— | |
| General and administrative | 7.7+7.2%— | 1.4−28.3%— | 1.7−21.0%— | 2.6*+67.2%— | 2.0+31.6%— | 2.0+5.7%— | 2.1−5.3%— | 1.5*−1.8%— | 1.5−5.6%— | 1.9—— | 2.3—— | 1.6r1.5*—— | 1.6r1.6—— | |
| Operating income | −24—— | −2.3—— | −16—— | −3.0*—— | −2.4—— | −2.5—— | −3.1—— | −3.2*—— | −3.7—— | −4.8—— | −5.0—— | −3.3*—— | −3.0—— | |
| Interest and finance income | 0.6−11.6%— | 0.2−10.5%— | 0.1−31.2%— | 0.1*−17.4%— | 0.2+23.2%— | 0.20.0%— | 0.2−12.8%— | 0.2*−32.9%— | 0.1−56.3%— | 0.2—— | 0.2—— | 0.2*—— | 0.3—— | |
| Other non-operating income (expense) | 0.5−82.2%— | 0.2−90.4%— | 0.1—— | 0.1*−95.3%— | 0.1—— | 1.6+191%— | −0.3−117%— | 2.8*—— | −1.1−338%— | 0.5—— | 1.6—— | −0.8*—— | 0.4—— | |
| Income before tax | −23—— | −2.1—— | −16—— | −2.9*—— | −2.3—— | −0.9—— | −3.4—— | −0.4*—— | −4.8—— | −4.3—— | −3.3—— | −4.1*—— | −2.6—— | |
| Income tax | −1.7—— | −0.0—— | 0—— | −1.7*—— | 0—— | 0—— | 0—— | −1.0*—— | −0.6—— | −0.9—— | −0.7—— | −0.9*—— | −0.2—— | |
| Net income attributable to shareholders | −21—— | −2.1—— | −16—— | −1.2*−285%— | −2.3—— | −0.9—— | −3.4—— | 0.6*—— | −4.2—— | −3.4—— | −2.6—— | −3.2*—— | −2.4—— | |
| Earnings per share, basic | — | -0.11—— | -0.91—— | — | -0.14—— | -0.06—— | -0.21—— | — | -0.36—— | -0.30—— | -0.24—— | — | -0.21—— | |
| Earnings per share, diluted | — | -0.11—— | -0.91—— | — | -0.14—— | -0.06—— | -0.21—— | — | -0.36—— | -0.30—— | -0.24—— | — | -0.21—— | |
| Shares, weighted average (basic) | 20+26.3%— | 20+26.3%— | 17+8.4%— | — | 17+47.2%— | 16+38.4%— | 16+45.7%— | — | 12−0.0%— | 12—— | 11—— | — | 12—— | |
| Shares, weighted average (diluted) | 20+26.3%— | 20+26.3%— | 17+8.4%— | — | 17+47.2%— | 16+38.4%— | 16+45.7%— | — | 12−0.0%— | 12—— | 11—— | — | 12—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 21—36.9% | 21+26.4%36.9% | 14−31.2%27.5% | 17−23.3%25.5% | 19+68.9%27.3% | 17+11.3%25.3% | 20+3.2%28.7% | 22−3.8%30.7% | 11−40.4%18.1% | 15—23.2% | 19—27.8% | 23—31.4% | 19—24.3% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | 0.0—0.0% | 0.0—0.0% | 0—0.0% | 6.6—8.6% | |
| Receivables | — | — | — | — | — | — | — | — | — | — | 0.4—0.6% | 0.7—1.0% | 1.0—1.3% | |
| Current assets | 22—38.1% | 22+27.0%38.1% | 14−30.2%28.6% | 17−23.5%26.1% | 19+60.9%28.1% | 17+7.7%26.0% | 21+0.5%29.4% | 23−5.4%31.5% | 12−55.6%19.5% | 16—24.6% | 20—29.3% | 24—32.8% | 27—35.3% | |
| Property, plant and equipment | — | — | — | 0.0−46.7%0.0% | — | — | — | 0.0−37.5%0.0% | — | — | — | 0.0—0.0% | — | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0.0—0.0% | |
| Goodwill | 8.1—14.1% | 8.10.0%14.1% | 8.10.0%16.3% | 8.10.0%12.2% | 8.10.0%11.9% | 8.10.0%12.2% | 8.10.0%11.7% | 8.10.0%11.3% | 8.10.0%13.3% | 8.1—12.5% | 8.1—11.7% | 8.1—11.1% | 8.1—10.7% | |
| Other intangible assets | 28—47.8% | 28−32.9%47.8% | 28−32.9%55.1% | 410.0%61.7% | 410.0%60.1% | 410.0%61.8% | 410.0%58.9% | 410.0%57.1% | 410.0%67.2% | 41—62.9% | 41—59.0% | 41—56.1% | 41—54.0% | |
| Total assets | 58—100% | 58−13.3%100% | 50−28.3%100% | 67−7.4%100% | 68+11.9%100% | 67+1.9%100% | 70+0.1%100% | 72−1.8%100% | 61−19.6%100% | 65—100% | 70—100% | 73—100% | 76—100% | |
| Accounts payable | 0.4—0.7% | 0.4−10.7%0.7% | 0.4−69.5%0.8% | 0.7+16.8%1.1% | 0.1−82.9%0.2% | 0.5−72.6%0.7% | 1.3−13.6%1.9% | 0.6−40.3%0.8% | 0.7−27.2%1.1% | 1.7—2.6% | 1.5—2.2% | 1.0—1.4% | 0.9—1.2% | |
| Current liabilities | 1.6—2.8% | 1.6+29.6%2.8% | 1.3−46.0%2.5% | 2.1+11.2%3.2% | 1.3−34.9%1.9% | 1.2−53.4%1.9% | 2.3−11.0%3.3% | 1.9+14.6%2.7% | 2.0+11.4%3.2% | 2.7—4.1% | 2.6—3.7% | 1.7—2.3% | 1.8—2.3% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | |
| Total liabilities | 2.2—3.8% | 2.2−41.0%3.8% | 1.9−70.2%3.7% | 2.8−48.8%4.1% | 3.6−60.4%5.3% | 3.8−59.2%5.6% | 6.3−39.6%9.0% | 5.4−53.4%7.5% | 9.1−21.0%14.8% | 9.2—14.1% | 10—14.9% | 12—15.8% | 12—15.1% | |
| Retained earnings | −246—−427% | −246—−427% | −244—−488% | −228—−343% | −227—−332% | −225—−338% | −224—−321% | −221—−307% | −221—−361% | −217—−332% | −214—−307% | −211—−288% | −208—−273% | |
| Shareholders' equity | 55—96.2% | 55−11.7%96.2% | 48−24.1%96.3% | 64−4.1%95.9% | 65+24.5%94.7% | 63+11.9%94.4% | 64+7.1%91.0% | 67+7.9%92.5% | 52−19.4%85.2% | 56—85.9% | 59—85.1% | 62—84.2% | 65—84.9% | |
| Total liabilities and equity | 58—100% | 58−13.3%100% | 50−28.3%100% | 67−7.4%100% | 68+11.9%100% | 67+1.9%100% | 70+0.1%100% | 72−1.8%100% | 61−19.6%100% | 65—100% | 70—100% | 73—100% | 76—100% | |
| Shares outstanding | 21—— | 21+48.9%— | 16+17.7%— | 16+16.8%— | 15+52.6%— | 14—— | 14—— | 14+45.9%— | 10—— | — | — | 9.4—— | — | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.6−25.8%— | 0.2*−4.4%— | 0.1−65.2%— | 0.2*+40.0%— | 0.1*−32.5%— | 0.2*+2.0%— | 0.3+26.9%— | 0.1*−43.2%— | 0.2*+48980%— | 0.2*—— | 0.2—— | 0.2*—— | 0.0—— | |
| Cash from operating activities | −8.9—— | −1.8*—— | −3.2—— | −1.7*—— | −2.2*—— | −3.1*—— | −1.8—— | −3.0*—— | −4.1*—— | −4.2*—— | −3.6—— | −2.1*—— | −1.9*—— | |
| Cash from investing activities | — | — | — | 0*—— | 0*−100%— | 0*—— | 0—— | 0*−100%— | 0.0*—— | 0*—— | −0.0—— | 6.5*—— | −6.6*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | |
| Cash from financing activities | 13−2.4%— | 9.3*—— | 0—— | 0*−100%— | 4.0*—— | 0*—— | −0.3—— | 14*—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | |
| Change in cash | 4.4+161%— | 7.6*—— | −3.2—— | −1.7*−115%— | 1.8*—— | −3.1*—— | −2.1—— | 11*+148%— | −4.1*—— | −4.2*—— | −3.6—— | 4.5*—— | −8.4*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Grace Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Mr. Kohli | $1.3 M | $1.9 M | $466 K | $63 |
| 2025Mr. Kohli | $1.1 M | $775 K | $432 K | $31 |
| 2024Chief executive | $998 K | $1.2 M | $430 K | $47 |
Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026
Events at Grace Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $10 M | Private placement after listing | $10 to $50 million | 9 | equity | SEC |
| Feb 2025 | $15 M | Private placement after listing | $10 to $50 million | 14 | equity, options | SEC |
| Sep 2023 | $8 M | Private placement after listing | $2 to $10 million | 4 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Grace Therapeutics, Inc. compares in Biotechnology
- Market cap$39 M · higher than 24% of 726
- Price / book0.6× · lower than 89% of 534
- FCF yield-25.7% · higher than 38% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Grace Therapeutics, Inc.🇺🇸 | $39 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Grace Therapeutics, Inc.? Verify and update this profile — free
Show Grace Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.